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1. Introduction
Bipolar depression is a common and costly condition. In 
this supplement, a group of experienced clinician-researchers 
review the substantial prevalence and burden as well as the 
diagnostic (especially differentiation from unipolar depression) 
and therapeutic (too few interventions with established efficacy, 
and those commonly have tolerability limitations) challenges 
of bipolar depression, in addition to describing the important 
advances in addressing these challenges.
In the first article of this supplement, Dr. Shefali Miller of 
Stanford, California, and associates examine the prevalence 
and burden of bipolar depression, reviewing substantial data 
indicating that depressive symptoms are more pervasive than 
mood elevation or mixed symptoms and, consequently, impose 
more burden on patients, caregivers, and society. Dr. Miller and 
associates conclude that, in light of its prevalence, pervasiveness, 
and costs, more effective treatments for bipolar depression are 
needed to mitigate its profound impact upon individuals and 
society.
In the next article, Dr. Robert Hirschfeld of Galveston, Texas, 
reviews the differential diagnosis of bipolar disorder and major 
depressive disorder, with these being particularly challenging to 
differentiate from one another, as patients with bipolar disorder 
spend most of their symptomatic time enduring depressive 
symptoms. Dr. Hirschfeld emphasizes that proper screening 
and comprehensive evaluation is necessary to avoid patients 
with bipolar disorder being misdiagnosed with unipolar major 
depressive disorder, and that accurate differentiation of these 
conditions has profound therapeutic implications. Dr. Hirschfeld 
also describes how several validated, easily administered 
screening instruments, as components of careful comprehensive 
evaluations, can help avoid patients with bipolar disorder being 
misdiagnosed with unipolar major depressive disorder, which can 
profoundly improve outcomes.
In the third article, Dr. Mark Frye of Rochester, Minnesota, 
and associates review current therapeutic options for bipolar 
depression, focussing not only on approved agents, but also 
unapproved alternatives such as mood stabilizers and anti-
depressants. Dr. Frye and associates also describe the substantial 
unmet need for interventions that are efficacious, effective, and 
have a low side-effect burden, and the fact that future research 
needs to not only establish efficacy and tolerability but also 
advance personalized therapeutics through the development of 
response biomarkers.
The next article, by Dr. Terence Ketter of Stanford, California, 
and associates describes use of number needed to treat and 
number needed to harm to quantify risks of benefits and harms 
for treatment selection in patients with bipolar depression. 
Dr. Ketter and associates demonstrate how efficacy and safety/
tolerability data from multicenter, randomized, double-blind, 
placebo-controlled trials and meta-analyses can be used for 
benefit versus harm risk assessments for older and newer acute 
bipolar depression treatments. Whereas older (olanzapine-
fluoxetine combination and quetiapine monotherapy) approved 
treatments with adequate efficacy but tolerability limitations 
may have utility in high-urgency situations, older (lamotrigine 
and antidepressants) and newer unapproved treatments with 
adequate tolerability but efficacy limitations may have utility in 
low-urgency situations. In contrast, the newly approved agent 
lurasidone, which combines adequate efficacy and tolerability, 
may ultimately prove useful in diverse situations.
Finally, Dr. David Kemp of Cleveland, Ohio, reviews manage-
ment of side effects of commonly used treatments for bipolar 
depression. Dr. Kemp describes how weight gain, metabolic 
dysregulation, sedation/somnolence, and akathisia can negatively 
affect treatment adherence and clinical responses, and reviews 
management options including lifestyle modifications such as diet 
and exercise, switching to medications with more favorable side-
effect profiles, and use of adjunctive medications if these other 
efforts at side-effect mitigation yield inadequate outcomes.
Although this supplement describes substantive advances in 
the diagnosis and treatment of bipolar depression, there clearly 
remain important unmet needs to enhance the management of 
this common and costly condition. Nevertheless, the important 
advances described in this supplement suggest that there is 
reason for optimism that ongoing research will yield additional 
diagnostic and therapeutic progress necessary to enhance 
outcomes for individuals struggling with bipolar depression.
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